CY1118351T1 - ΑΔΕΝΟΪΟΣ ΑΠΟΤΕΛΟΥΜΕΝΟΣ ΑΠΟ ΠΡΩΤΕΪΝΗ ΕΞΩΝΙΟΥ ΚΑΨΙΔΙΟΥ SAdV-39 ΑΔΕΝΟΪΟΥ Ε ΠΙΘΗΚΟΥ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ - Google Patents

ΑΔΕΝΟΪΟΣ ΑΠΟΤΕΛΟΥΜΕΝΟΣ ΑΠΟ ΠΡΩΤΕΪΝΗ ΕΞΩΝΙΟΥ ΚΑΨΙΔΙΟΥ SAdV-39 ΑΔΕΝΟΪΟΥ Ε ΠΙΘΗΚΟΥ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ

Info

Publication number
CY1118351T1
CY1118351T1 CY20161101281T CY161101281T CY1118351T1 CY 1118351 T1 CY1118351 T1 CY 1118351T1 CY 20161101281 T CY20161101281 T CY 20161101281T CY 161101281 T CY161101281 T CY 161101281T CY 1118351 T1 CY1118351 T1 CY 1118351T1
Authority
CY
Cyprus
Prior art keywords
sadv
sabvatic
extractor
miscellaneous uses
extensional
Prior art date
Application number
CY20161101281T
Other languages
English (en)
Inventor
Soumitra Roy
James M Wilson
Luc H Vandenberghe
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of CY1118351T1 publication Critical patent/CY1118351T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Ένας ανασυνδυασμένος φορέας αποτελείται από αλληλουχίες αδενοϊού πιθήκου SAdV-39, -25.2, -26, -30, -37 και -38 και ένα ετερόλογο γονίδιο υπό τον έλεγχο ρυθμιστικών αλληλουχιών. Επίσης αποκαλύπτεται μια κυτταρική σειρά η οποία εκφράζει γονίδιο(α) αδενοϊού πιθήκου SAdV-39, -25.2, -26, -30, -37 και -383. Παρέχονται μέθοδοι χρήσης των φορέων και κυτταρικών σειρών.
CY20161101281T 2007-11-28 2016-12-13 ΑΔΕΝΟΪΟΣ ΑΠΟΤΕΛΟΥΜΕΝΟΣ ΑΠΟ ΠΡΩΤΕΪΝΗ ΕΞΩΝΙΟΥ ΚΑΨΙΔΙΟΥ SAdV-39 ΑΔΕΝΟΪΟΥ Ε ΠΙΘΗΚΟΥ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ CY1118351T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US449907P 2007-11-28 2007-11-28
US446107P 2007-11-28 2007-11-28
US453207P 2007-11-28 2007-11-28
US450707P 2007-11-28 2007-11-28
US454107P 2007-11-28 2007-11-28
US446407P 2007-11-28 2007-11-28
PCT/US2008/013066 WO2009073104A2 (en) 2007-11-28 2008-11-24 Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38

Publications (1)

Publication Number Publication Date
CY1118351T1 true CY1118351T1 (el) 2017-06-28

Family

ID=40380705

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101281T CY1118351T1 (el) 2007-11-28 2016-12-13 ΑΔΕΝΟΪΟΣ ΑΠΟΤΕΛΟΥΜΕΝΟΣ ΑΠΟ ΠΡΩΤΕΪΝΗ ΕΞΩΝΙΟΥ ΚΑΨΙΔΙΟΥ SAdV-39 ΑΔΕΝΟΪΟΥ Ε ΠΙΘΗΚΟΥ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ

Country Status (20)

Country Link
US (3) US8685387B2 (el)
EP (2) EP2220241B1 (el)
JP (3) JP5740158B2 (el)
KR (3) KR101662574B1 (el)
CN (1) CN101883858B (el)
AU (1) AU2008331906B2 (el)
BR (1) BRPI0819783A2 (el)
CA (2) CA2706258C (el)
CY (1) CY1118351T1 (el)
DK (1) DK2220241T3 (el)
ES (1) ES2607029T3 (el)
HR (1) HRP20161573T1 (el)
HU (1) HUE032142T2 (el)
LT (1) LT2220241T (el)
MX (2) MX2010005858A (el)
PL (1) PL2220241T3 (el)
PT (1) PT2220241T (el)
SG (1) SG10201604001XA (el)
SI (1) SI2220241T1 (el)
WO (1) WO2009073104A2 (el)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
DK2220242T3 (en) 2007-11-28 2017-03-27 Univ Pennsylvania ABE-ADENOVIRA OF GROUP B, SADV-28,27, -29, -32, -33 AND -35 AND APPLICATIONS THEREOF
CA2706258C (en) 2007-11-28 2017-06-06 The Trustees Of The University Of Pennsylvania Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
EP2774985B1 (en) 2008-10-31 2016-12-14 The Trustees Of The University Of Pennsylvania Simian adenovirus SAdV-43 and uses thereof
KR101763093B1 (ko) * 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
WO2011057254A2 (en) * 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
AU2010314842A1 (en) * 2009-11-09 2012-05-31 Genvec, Inc. Methods of propagating monkey adenoviral vectors
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
ES2696551T3 (es) * 2010-12-17 2019-01-16 Globeimmune Inc Composiciones y métodos para el tratamiento o la prevención de la infección por adenovirus-36 humano
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
US9267112B2 (en) 2011-05-10 2016-02-23 The Regents Of The University Of California Adenovirus isolated from Titi Monkeys
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
CN105473723A (zh) 2012-05-18 2016-04-06 宾夕法尼亚大学托管会 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途
PL2880160T3 (pl) * 2012-08-03 2019-03-29 Cedars-Sinai Medical Center Izolowanie wzmacniających transport mutantów białka dostarczającego lek
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
WO2016057387A1 (en) 2014-10-06 2016-04-14 The Trustees Of The University Of Pennsylvania Compositions and methods for isolation of circulating tumor cells (ctc)
WO2016073693A2 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US11254711B2 (en) * 2015-06-12 2022-02-22 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CA3006569A1 (en) * 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR102471633B1 (ko) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
EP3458589A4 (en) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
EP3654860A1 (en) 2017-07-17 2020-05-27 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
MX2020004492A (es) * 2017-10-31 2020-11-24 Janssen Vaccines & Prevention Bv Adenovirus y usos de los mismos.
CN111295391B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
CA3077630A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
US20210301305A1 (en) 2018-06-13 2021-09-30 Voyager Therapeutics, Inc. Engineered untranslated regions (utr) for aav production
WO2020023612A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
US20210348242A1 (en) 2018-10-04 2021-11-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
TW202028458A (zh) 2018-10-05 2020-08-01 美商航海家醫療公司 編碼腺相關病毒(aav)生產蛋白之經基因工程化核酸構築體
TW202028468A (zh) 2018-10-15 2020-08-01 美商航海家醫療公司 用於桿狀病毒/Sf9系統中rAAV之大規模生產的表現載體
EP3917566A4 (en) 2019-01-31 2022-10-26 Oregon Health & Science University METHODS OF USING DIRECTED, TRANSCRIPTION-DEPENDENT EVOLUTION OF AAV CAPSIDS
WO2022013221A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022218997A1 (en) 2021-04-12 2022-10-20 Centre National De La Recherche Scientifique (Cnrs) Novel universal vaccine presenting system
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1364343A1 (ru) 1984-07-13 1988-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Способ получени человеческого лейкоцитарного интерферона альфа-2
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4732683A (en) 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
WO1996012406A1 (en) 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
ES2240980T3 (es) 1994-10-28 2005-10-16 The Trustees Of The University Of Pennsylvania Adenovirus mejorado y metodos de utilizacion del mismo.
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
AU722624B2 (en) 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
AU9397098A (en) 1997-09-19 1999-04-12 Trustees Of The University Of Pennsylvania, The Methods and cell line useful for production of recombinant adeno-associated viruses
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU1822499A (en) 1997-12-12 1999-06-28 Saint Louis University Ctip, a novel protein that interacts with ctbp and uses therefor
ATE286138T1 (de) 1998-03-20 2005-01-15 Univ Pennsylvania Zusammensetzungen und verfahren zur helfer-freien herstellung von rekombinante adeno-assoziierten viren
US6210663B1 (en) 1998-08-20 2001-04-03 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
CZ20022643A3 (cs) 2000-01-31 2003-02-12 Smithkline Beecham Biologicals S. A. Farmaceutický prostředek
WO2001058940A2 (en) 2000-02-09 2001-08-16 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
ATE530672T1 (de) 2001-06-22 2011-11-15 Univ Pennsylvania Rekombinante adenoviren mit affen-adenovirus proteinen und verwendung davon.
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
BR0214350A (pt) * 2001-11-21 2005-05-10 Univ Pennsylvania Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
ES2478625T3 (es) * 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos
CN107723298A (zh) * 2004-01-23 2018-02-23 Msd意大利有限公司 黑猩猩腺病毒疫苗载运体
EP1718315A4 (en) 2004-02-06 2008-08-13 Univ Monash HIGH-DOSE USE AND SHORT INTERVAL OF SULFATE POLYSACCHARIDES IN THE TREATMENT OF INFECTIONS
BRPI0518146A (pt) 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
WO2006085092A2 (en) 2005-02-12 2006-08-17 Viranative Ab Methods and uses of antibodies in the purification of interferon
CN101384722A (zh) * 2005-05-12 2009-03-11 葛兰素集团有限公司 疫苗组合物
WO2008010864A2 (en) 2006-04-28 2008-01-24 The Trustees Of The University Of Pennsylvania Modified adenovirus hexon protein and uses thereof
CA2706258C (en) 2007-11-28 2017-06-06 The Trustees Of The University Of Pennsylvania Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
DK2220242T3 (en) * 2007-11-28 2017-03-27 Univ Pennsylvania ABE-ADENOVIRA OF GROUP B, SADV-28,27, -29, -32, -33 AND -35 AND APPLICATIONS THEREOF
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
WO2013055268A1 (en) 2011-10-13 2013-04-18 Telefonaktiebolaget L M Ericsson (Publ) Method and node related to channel estimation

Also Published As

Publication number Publication date
AU2008331906A1 (en) 2009-06-11
CA2964396A1 (en) 2009-06-11
LT2220241T (lt) 2016-12-12
KR20150108945A (ko) 2015-09-30
KR101761691B1 (ko) 2017-07-26
US20160244783A1 (en) 2016-08-25
KR101614364B1 (ko) 2016-04-22
JP2011522513A (ja) 2011-08-04
HUE032142T2 (en) 2017-08-28
WO2009073104A8 (en) 2016-03-31
HRP20161573T1 (hr) 2017-02-10
CN101883858B (zh) 2015-07-22
EP2220241B1 (en) 2016-09-14
JP5740158B2 (ja) 2015-06-24
PL2220241T3 (pl) 2017-06-30
MX347246B (es) 2017-04-19
KR20160118370A (ko) 2016-10-11
WO2009073104A2 (en) 2009-06-11
SI2220241T1 (sl) 2017-02-28
BRPI0819783A2 (pt) 2015-06-23
US9359618B2 (en) 2016-06-07
KR20100109915A (ko) 2010-10-11
SG10201604001XA (en) 2016-07-28
US20140155476A1 (en) 2014-06-05
US20100247490A1 (en) 2010-09-30
MX2010005858A (es) 2010-06-11
CA2706258A1 (en) 2009-06-11
WO2009073104A3 (en) 2009-08-20
JP6224769B2 (ja) 2017-11-01
KR101662574B1 (ko) 2016-10-05
CN101883858A (zh) 2010-11-10
CA2706258C (en) 2017-06-06
DK2220241T3 (en) 2017-01-09
JP2015083006A (ja) 2015-04-30
EP2220241A2 (en) 2010-08-25
PT2220241T (pt) 2016-12-26
US8685387B2 (en) 2014-04-01
ES2607029T3 (es) 2017-03-28
AU2008331906B2 (en) 2014-03-06
EP3128010A1 (en) 2017-02-08
JP2016195595A (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
CY1118351T1 (el) ΑΔΕΝΟΪΟΣ ΑΠΟΤΕΛΟΥΜΕΝΟΣ ΑΠΟ ΠΡΩΤΕΪΝΗ ΕΞΩΝΙΟΥ ΚΑΨΙΔΙΟΥ SAdV-39 ΑΔΕΝΟΪΟΥ Ε ΠΙΘΗΚΟΥ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ
WO2009136977A3 (en) Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
CY1118866T1 (el) Αδενοϊοι της υπο-οικογενειας β των πιθηκων sadv-28,27,-29,-32,-33, και -35 και χρησεις αυτων
MX2010005860A (es) Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos.
DK2012822T3 (da) Modificeret adenovirushexonprotein og anvendelser deraf
WO2012071318A3 (en) Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
BR112014028684A2 (pt) subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
CY1124627T1 (el) Στοχευμενη τροποποιηση γονιδιωματος αρουραιου
MX2021000128A (es) Aav variante y composiciones, métodos y usos para transferencia génica a células, órganos y tejidos.
NZ741778A (en) Multiplexed genome editing
MX2022015080A (es) Variantes de hsd17b13 y usos de las mismas.
ATE494381T1 (de) Verbesserte expressionselemente
EP1771570A4 (en) ADDITION OF TRANSGENES IN ADENOVIRUS VECTORS
NO20042191L (no) Simian-adenovirusnukleinsyre og aminosyresekvenser, vektorer inneholdende disse, og fremgangsmater for deres anvendelse
WO2008076322A3 (en) Novel laccases, compositions and methods of use
NO20092650L (no) Flytende detergentblanding
EP3508577A3 (en) Modified amadoriase capable of acting on fructosyl hexapeptide
MX2011006779A (es) Lacasas y metodos de uso de las mismas a temperatura baja.
CY1122757T1 (el) Συνθεση κατα του αποχρωματισμου
EA201170854A1 (ru) Система единичной рекомбинации и способы применения
ATE532861T1 (de) Expressionsvektor
DE60228609D1 (de) Identifizierung und charakterisierung von genen
MX2010001422A (es) Una region reguladora de planta que dirige la expresion de transgen en el tejido maternal y de soporte de ovulos de maiz y semillas polinizadas.
MX2019001142A (es) Estabilizante para dispersiones de poliolefina en poliol polieter.
WO2008124111A3 (en) System for pulling out regulatory elements in vitro